When the other company is done with R&D and creates a drug that makes it to the market, my understanding is that patents "violated" during development mean nothing, as the final product is not covered by patented methods used to discover it.
WHOA! If that's true, 1) that's very, very disturbing, and 2) MNTA has acted quickly and accordingly.
It will be more than interesting to see what responses you get.